Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer

Abstract The androgen receptor signaling inhibitor enzalutamide (Enz) is one the primary therapeutic drugs for advanced prostate cancer (PCa). Nevertheless, most of patients ultimately develop resistance to Enz. Through an integrated analysis of CRISPR genome-wide and kinome-wide screens, coupled wi...

Full description

Bibliographic Details
Published in:	Biomarker Research
Main Authors:	Fu-Hao Ji, Yu-Hang Qian, Xiu-Chen Guo, Hai-Hong Liao, Jia-Cheng Huang, Zi-Han Xu, Ming-Ming Yu, Yan-Yuan Wu, Jie-Wen Bao, Hao-Jie Chen, Yong-Jiang Yu, Lin Wang
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Subjects:	Prostate cancer Enzalutamide RPS6KC1 scRNA-seq
Online Access:	https://doi.org/10.1186/s40364-025-00822-x

Similar Items

An androgen receptor-based signature to predict prognosis and identification of ORC1 as a therapeutical target for prostate adenocarcinoma
by: Linjin Li, et al.
Published: (2024-03-01)

Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis
by: Ahmet Dirican, et al.
Published: (2022-11-01)

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
by: Zhe Zhu, et al.
Published: (2024-11-01)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
by: Nair Lopes, et al.
Published: (2021-08-01)

Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Pedro Cardoso, et al.
Published: (2020-05-01)

Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study
by: Sung Hee Lim, et al.
Published: (2024-03-01)

Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
by: Zhu Wen, et al.
Published: (2024-08-01)

Integrated bioinformatics analysis reveals that OPRK1 inhibits ferroptosis and induces enzalutamide resistance in prostate cancer
by: Liangrong Zhang, et al.
Published: (2025-04-01)

Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
by: Xu Wen, et al.
Published: (2023-05-01)

ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer
by: Jinpeng Cen, et al.
Published: (2025-06-01)

Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
by: Stefanie Fischer, et al.
Published: (2020-01-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer
by: Jinpeng Cen, et al.
Published: (2025-06-01)

Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathway
by: Hui-Yu Dong, et al.
Published: (2023-01-01)

Bulk RNA-seq conjoined with ScRNA-seq analysis reveals the molecular characteristics of nucleus pulposus cell ferroptosis in rat aging intervertebral discs
by: Shipeng Chen, et al.
Published: (2025-04-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01)

Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer
by: Yuanfa Feng, et al.
Published: (2023-03-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01)

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide
by: Phoebe A. Tsao, et al.
Published: (2023-08-01)

Unveiling novel insights in prostate cancer through single-cell RNA sequencing
by: Wenyue Yu, et al.
Published: (2023-09-01)

Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy
by: Francesca Fiorentino, et al.
Published: (2023-04-01)

High-fat diet promotes prostate cancer metastasis via RPS27
by: Dameng Li, et al.
Published: (2024-02-01)

Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel
by: Hakan Taban, et al.
Published: (2025-06-01)

DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity
by: Nicolas Malaquin, et al.
Published: (2020-07-01)

Enzalutamide induced non-ischemic cardiomyopathy. A case report and review of literature on anti-androgen therapy-related cardiovascular events
by: Aswini Kumar, et al.
Published: (2023-01-01)

Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report
by: Thomson A, et al.
Published: (2024-10-01)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: Luo J, et al.
Published: (2016-11-01)

Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran
by: Zahra Goudarzi, et al.
Published: (2024-02-01)

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
by: Yan Li, et al.
Published: (2022-11-01)

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
by: Xiang Gao, et al.
Published: (2024-08-01)

Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review
by: Zineddine Belabaci, et al.
Published: (2025-05-01)

A rare case of idiopathic cholestasis: Clinical conundrums complicating enzalutamide therapy in metastatic prostate cancer
by: Jun Liu, et al.
Published: (2019-11-01)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
by: Taro Iguchi, et al.
Published: (2019-04-01)

Infiltrating lipid-rich macrophage subpopulations identified as a regulator of increasing prostate size in human benign prostatic hyperplasia
by: Nadia Atallah Lanman, et al.
Published: (2025-01-01)

KC-bitopological spaces
by: Hamza Qoqazeh, et al.
Published: (2024-11-01)

Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
by: Onur Baser, et al.
Published: (2024-04-01)

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience
by: T. V. Ustinova, et al.
Published: (2021-12-01)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
by: Xiangyun You, et al.
Published: (2023-04-01)

Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients
by: Ali Alkan, et al.
Published: (2021-09-01)

Possibilities of treatment of patients with castrationrefractory prostate cancer using enzalutamide
by: B. Ya. Alekseyev, et al.
Published: (2019-12-01)